Abstract
Dupilumab (Dupixent) has been approved to treat eosinophilic esophagitis in adults and children ages 12 years and older who weigh at least 40 kilograms. This is the first drug approved to treat this disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have